ZA202109826B - Nk1 inhibitors for the treatment of malaria - Google Patents

Nk1 inhibitors for the treatment of malaria

Info

Publication number
ZA202109826B
ZA202109826B ZA2021/09826A ZA202109826A ZA202109826B ZA 202109826 B ZA202109826 B ZA 202109826B ZA 2021/09826 A ZA2021/09826 A ZA 2021/09826A ZA 202109826 A ZA202109826 A ZA 202109826A ZA 202109826 B ZA202109826 B ZA 202109826B
Authority
ZA
South Africa
Prior art keywords
malaria
inhibitors
treatment
Prior art date
Application number
ZA2021/09826A
Inventor
Manuel Vicente Salinas-Martin
Original Assignee
Plus Vitech S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plus Vitech S L filed Critical Plus Vitech S L
Publication of ZA202109826B publication Critical patent/ZA202109826B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2021/09826A 2019-05-08 2021-12-01 Nk1 inhibitors for the treatment of malaria ZA202109826B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382353 2019-05-08
PCT/EP2020/062521 WO2020225283A1 (en) 2019-05-08 2020-05-06 Nk1 inhibitors for the treatment of malaria

Publications (1)

Publication Number Publication Date
ZA202109826B true ZA202109826B (en) 2022-09-28

Family

ID=66529943

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/09826A ZA202109826B (en) 2019-05-08 2021-12-01 Nk1 inhibitors for the treatment of malaria

Country Status (2)

Country Link
WO (1) WO2020225283A1 (en)
ZA (1) ZA202109826B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114425053B (en) * 2022-02-25 2022-10-25 中国农业科学院兰州兽医研究所 Application of aprepitant compound in preparation of drugs for preventing or treating African swine fever
US11883411B2 (en) 2022-02-25 2024-01-30 Lanzhou Veterinary Research Institute, Chinese Academy Of Agricultural Sciences Use of compound aprepitant in preparation of drug for preventing or treating African swine fever (ASF)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184819A1 (en) * 2007-07-19 2010-07-22 Robert Vink Method for reducing intracranial pressure

Also Published As

Publication number Publication date
WO2020225283A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
IL292642A (en) Ras inhibitors
IL292643A (en) Ras inhibitors
IL292644A (en) Ras inhibitors
IL279260A (en) Kdm1a inhibitors for the treatment of disease
IL288920A (en) Glycolate oxidase inhibitors for the treatment of disease
IL287902A (en) Methods for the administration of certain vmat2 inhibitors
IL283948A (en) Methods for the treatment of depression
IL291735A (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
ZA202109826B (en) Nk1 inhibitors for the treatment of malaria
IL286000A (en) Esketamine for the treatment of depression
IL308476A (en) Inhibitors of the menin-mll interaction
IL290319A (en) Compound for combination treatment
IL288234A (en) Compounds for the treatment of neuromuscular disorders
IL287250A (en) Method of treatment
IL286857A (en) Methods for the treatment of beta-thalassemia
ZA202105399B (en) Use of spiropidion
ZA202006591B (en) Compositions for the treatment of hypertension
IL280312A (en) Process for the preparation of bromodomain inhibitor
GB201907305D0 (en) Treatment of conditions
GB201902634D0 (en) Apparatus for the treatment of malaria
IL290983A (en) Methods of treatment
SG11202108022RA (en) Use of igfbp7 for treating malaria
GB201917253D0 (en) Treatment of conditions
GB201901130D0 (en) Formulation for the treatment of tendinopathies
GB201918853D0 (en) Methods of treatment